Sai Parenteral IPO saw 43% subscription on Day 3, with strong NII interest but weak retail participation. Despite no GMP indicating a flat listing, brokerages recommend subscribing for the long term, citing growth potential in injectables and CDMO segments, though valuations appear at a premium compared to peers.
